BGMD — BG Medicine Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$1.52m
- $1.57m
Annual income statement for BG Medicine, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2011 December 31st | 2012 December 31st | 2013 December 31st | 2014 December 31st | 2015 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.63 | 2.81 | 4.07 | 2.79 | 1.57 |
Cost of Revenue | |||||
Gross Profit | 1.01 | 1.86 | 2.68 | 1.83 | 1.06 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 19.1 | 25.5 | 18.4 | 10.1 | 6.2 |
Operating Profit | -17.5 | -22.7 | -14.4 | -7.36 | -4.63 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -17.6 | -23.8 | -15.8 | -8.06 | -5.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -17.6 | -23.8 | -15.8 | -8.06 | -5.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -17.6 | -23.8 | -15.8 | -8.06 | -5.3 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -17.7 | -23.8 | -15.8 | -8.06 | -6.96 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -4.01 | -4.7 | -2.33 | -0.986 | -0.724 |
Dividends per Share |